Holen Sie sich die Stockscreener-App
0.00
100.00%
-2.36
Schlusskurs vom Vortag:
$2.36
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
$257.55M
Nettoeinkommen (Verlust:
$11.95M
KGV:
0.00
EPS:
0.91
Netto-Cashflow:
$-9.39M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-81.21%
1J Leistung:
-93.26%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$2.90
Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile
Vergleichen Sie EGRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EGRX
Eagle Pharmaceuticals Inc
|
0.00 | 0 | 257.55M | 11.95M | -9.39M | 0.91 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.75 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
154.96 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
9.96 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.68 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.40 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2018-11-01 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2018-10-31 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-03-21 | Bestätigt | Mizuho | Underperform |
| 2017-11-09 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-06 | Bestätigt | Mizuho | Underperform |
| 2017-07-27 | Bestätigt | Mizuho | Underperform |
| 2017-07-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-05-09 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-01-09 | Herabstufung | Mizuho | Neutral → Underperform |
| 2016-11-16 | Herabstufung | Mizuho | Buy → Neutral |
| 2016-11-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2016-11-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-26 | Bestätigt | Mizuho | Buy |
| 2016-08-16 | Bestätigt | Mizuho | Neutral |
| 2016-06-20 | Herabstufung | Mizuho | Buy → Neutral |
| 2016-05-10 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-03-18 | Bestätigt | Mizuho | Buy |
| 2016-02-26 | Bestätigt | Mizuho | Buy |
| 2015-12-09 | Eingeleitet | Mizuho | Buy |
| 2015-07-29 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Eagle Pharmaceuticals Inc Aktie (EGRX) Neueste Nachrichten
ACA Pharma secures fast-track approval for Eagle Pharmaceuticals' RYANODEX® in Macau - PRWeb
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ... - Eagle-Tribune
UPDATENika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June ... - Eagle-Tribune
Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Eagle-Tribune
Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th - Eagle-Tribune
U.S. Vasopressin Market Projected to Witness Massive Growth in Critical Care | Pfizer, Ferring Pharmaceuticals - openPR.com
EGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm! - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
EGRX STOCKHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
EGRX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Most Pittsburgh area Rite Aid locations to transfer prescriptions to Giant Eagle Pharmacy - Yahoo Finance
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - Eagle-Tribune
Heparin-Induced Thrombocytopenia (HIT) Market: A Serious Drug Reaction Explained 2025-2033 - openPR.com
Bacterial Pneumonia Market: How to Identify and Treat This Serious Lung Infection - openPR.com
ATNM DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. ... - Eagle-Tribune
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering - Eagle-Tribune
Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - Eagle-Tribune
Shareholders that lost money on Eagle Pharmaceuticals, Inc. (EGRX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a ... - Eagle-Tribune
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com - Defense World
Bacterial Pneumonia Therapeutics Market 2032: Clinical - openPR.com
INVESTOR ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc. (EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc. (EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors ... - Eagle-Tribune
Press Release Distribution & PR Platform - ACCESS Newswire
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com - The AM Reporter
EmpiRx Health Partners with Giant Eagle to Transform Pharmacy Benefits Care - PR Newswire
Eagle Pharmaceuticals Shares Turn Positive After Positive 2022 Outlook - marketscreener.com
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender AgreementHagens Berman - ACCESS Newswire
Latham Watkins Advises Eagle Pharmaceuticals in Royalty Monetization With Blue Owl Capital - Latham & Watkins LLP
Eagle Pharmaceuticals Announces $69 Mln Agreement To Monetize Bendeka Royalties - marketscreener.com
Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties - The Manila Times
Major Cash Injection: Eagle Pharma Lands $69M Through Strategic Royalty Sale - Stock Titan
StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Below 200-Day Moving Average – Here’s Why - Defense World
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan - The Manila Times
Eagle Pharmaceuticals announces amendment to limited duration stockholder rights plan - Marketscreener.com
Eagle Pharmaceuticals Doubles Anti-Takeover Protection to $20 in Rights Plan Update - Stock Titan
Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com - Defense World
Eagle Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by IFP Advisors Inc - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Eagle Pharmaceuticals, Inc. (EGRX) - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Finanzdaten der Eagle Pharmaceuticals Inc-Aktie (EGRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
Kapitalisierung:
|
Volumen (24h):